

INVESTOR PRESENTATION

WITH Q3 2026 FINANCIAL HIGHLIGHTS

MariMed

Forward Looking Statement Disclaimer

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This presentation includes information, statements, beliefs, and opinions which are forward-looking, and which reflect current estimates, expectations, and projections about future events, referred to herein and which constitute "forward-looking statements" or "forward-looking information" within the meaning of Canadian and U.S. securities laws. Statements containing words such as "believe", "expect", "intend", "should", "seek", "anticipate", "will", "positioned", "plan", "may", "estimate", "could", "continue", "outlook", "strategy", "initiative", "foreseeable", "potential", "guidance", "future", "priorities", "opportunity", "likely", or, in each case, their negative, plural, and words of similar meaning are intended to identify forward-looking statements. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions concerning, among other things, the Company's anticipated business strategies, anticipated trends in the Company's business, and anticipated market share, that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods. Although the Company has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated, or intended, including those described in the Risk Factors section of our Forms 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission. Forward-looking information contained in this presentation is based on the Company's current estimates, expectations and projections, which the Company believes are reasonable as of the current date. The Company can give no assurance that these estimates, expectations and projections will prove to have been correct. You should not place undue reliance on forward-looking statements, which are based on the information available as of the date of this document. Forward-looking statements contained in this document are made as of the date of this presentation and, except as required by applicable law, the Company assumes no obligation to update or revise them to reflect new events or circumstances.

Historical statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. In this regard, certain financial information contained herein has been extracted from, or based upon, information available in the public domain and/or provided by the Company. In particular historical results should not be taken as a representation that such trends will be replicated in the future. No statement in this document is intended to be nor may be construed as a profit forecast.

CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION: To the extent any forward-looking information in this presentation constitutes "future oriented financial information" or "financial outlooks" within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out above under the heading "Cautionary Note Regarding Forward-Looking Information". MariMed's actual financial position and results of operations may differ materially from management's current expectations and, as a result, MariMed's revenue and expenses may differ materially from the revenue and expenses profiles provided in this presentation. Such information is presented for illustrative purposes only and may not be an indication of Vireo's actual financial position or results of operations.

NON-GAAP FINANCIAL MEASURES: Non-GAAP Gross margin, Non-GAAP Net loss, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA margin and Non-GAAP Operating working capital are non-GAAP measures and do not have standardized definitions under U.S. GAAP accounting principles. As there are no standardized methods of calculating non-GAAP measurements, the Company's calculations may differ from those used by analysts, investors and other companies, even those within the cannabis industry, and therefore may not be directly comparable to similarly titled measured by others. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.



We’re on a Mission to Improve Lives Through the Power of Cannabis.

MariMed

OUR GROWTH STRATEGY

Expand the Brand

Grow MariMed's portfolio of leading cannabis brands through innovation, category expansion, and differentiated consumer experiences.

- New product innovation across core brands
- Strengthen leadership in edibles and beverages
- Increase brand awareness and market share
- Drive repeat consumer behavior

Scale Distribution

Expand wholesale penetration and asset-light market expansion through licensing, strategic partnerships, and disciplined M&A.

- Expand distribution across existing core markets
- Licensing and MSA expansion into new states
- Broaden retail and wholesale footprint
- Focus on high-ROIC growth opportunities

Deepen Consumer Loyalty

Increase customer lifetime value through retail engagement, loyalty programs, personalization, and experiential retail.

- Grow loyalty membership and retention

FOUNDATIONAL ADVANTAGES

Strong Brand Portfolio

- Award-winning brands with leading market positions across core states

Disciplined Capital Allocation

- Focus on profitability, operating leverage, and cash flow generation

Scalable Vertical Model

- Integrated cultivation, production, retail, and wholesale platform designed for long-term growth

MARIMED BY THE NUMBERS

$160M
2025 REVENUE

900+
EMPLOYEES

8
STATES
inc. footprint + licensing partnerships

14
DISPENSARIES

7
FACILITIES Cultivation and Production
~510K+ sq ft
(inc. PA facility under Mgmt.)

52M+
POPULATION


~$11b
TAM

720+
WHOLESALE ACCOUNTS

5
BRANDS
#1 Edible & #4 Beverage Across Core States

Data as of September 2026

FOOTPRINT & PORTFOLIO OF ASSETS



WHY MARIMED WINS

Leading Cannabis CPG Platform

- #1 edible brand across core markets
- Expanding beverage leadership
- Portfolio designed for repeat consumer behavior

Scalable Wholesale Engine

- 64% dispensary penetration
- 720+ wholesale accounts
- Asset-light licensing strategy expanding reach

Retail + Loyalty Ecosystem

- 432K loyalty members
- 80% of retail revenue tied to members
- Higher basket sizes and repeat purchase behavior

Proven Execution

- 27 consecutive quarters of positive Adjusted EBITDA
- Disciplined capital allocation
- Strong operating infrastructure

Multiple Near-Term Catalysts

- Columbus, OH dispensary
- New York licensing
- Federal reform optionality
- December 2026 Hemp ban

Management Team

- Proven multi-state operators
- Successfully navigated pricing compression, regulatory shifts, and capital market disruption
- Focused on liquidity, disciplined capital allocation, and shareholder value creation



WHOLESALE: DRIVING OUR BRAND MOMENTUM

STRONG PERFORMANCE

- Wholesale accounted for **44% of 3Q 2026 revenue**

BRAND PENETRATION

- **64% penetration** across core states during 3Q 2026
- Brand portfolio market share grew **150 bps**

STRATEGIC DISTRIBUTION

- Product placements in **720+ dispensaries** across 6 states
- Licensing third-party distribution provides **low-cost entry to new markets**

Betty's Eddies EST. 2014

Nature's Heritage™ Cannabis

Vibations Cannabis + Electrolyte Drink Mix

IN HOUSE™

Bubby's Baked™



A PORTFOLIO OF TOP-SELLING BRANDS*

- **Betty's Eddies™** - #1 edible in MA, MD & DE
- **Bubby's Baked™** - #1 baked goods edible in MA, MD & IL
- **Vibations™ Drink Mix –** Top 10 beverage in MA, MD & IL
- **InHouse™** – Top 10 gummy in MA, MD & DE
- **Nature's Heritage™ -** #1 flower brand in DE

*based on BDSA and Lit Alerts data for MA, MD, IL, and DE

BETTY'S EDDIES EST. 2014


Nature's HERITAGE™ CANNABIS


Vibations CANNABIS + ELECTROLYTE DRINK MIX

IN HOUSE™

BUBBY'S BAKED™

CONTINUING TO EXPAND ACROSS CORE MARKETS





85% Dispensary Penetration in 2025



STRONG RETAIL EXPERIENCE

STRONG RETAIL BRAND & PRESENCE

- **14 dispensaries** across MA, IL, MD, DE, and OH
- Strong presence under unified **Thrive** retail brand, app, and website

CONSUMER EXPERIENCE


- Curated, wellness-focused retail environments with premium design
- Deep community engagement with veterans, caregivers, and local partners

RETAIL PERFORMANCE HIGHLIGHTS:

- **55%** of total Q3 2026 revenue
- **7% year over year increase in transactions** in 3Q 2026

THRIVE™ DISPENSARY

STRONG LOYALTY MEMBER GROWTH



Data-Driven Personalization Delivered:

- **Membership +31%** year to date growth through Q3 2026
- Drove **80% of retail revenue in Q3 2026**
- **1% higher avg basket vs non-members** in Q3 2026

High-value customers are choosing MariMed — and coming back.

MANAGEMENT TEAM



Jon Levine
CEO & President

Co-founder of MariMed with two decades in the cannabis industry. Led the company from inception, leveraging deep experience in finance, real estate, and healthcare operations.



Timothy Shaw
Chief Operating Officer

Oversees all cultivation, production, and retail operations across 9 states; 20+ years in operations and horticulture; drives MariMed's industry-leading yields, product quality, and compliance systems.



Howard Schacter
Chief Communications Officer

Veteran communications leader with experience at Acreage Holdings, Facebook, Microsoft, and Spotify; award-winning brand strategist strengthening MariMed's visibility and consumer engagement.




Mario Pinho
Chief Financial Officer

CPA with 25+ years in global finance leadership; former CFO of Rakuten USA and senior executive at American Express and KPMG; brings expertise in scaling high-growth organizations with financial discipline.



Ryan Crandall
Chief Commercial Officer

Leads wholesale, retail, marketing, and product development; co-creator of Betty's Eddies™, MariMed's flagship edible brand; background in executive roles at RSA Security and EMC2.



Marlo Richard
VP of Human Resources

Experienced HR leader from AspenTech, Mimecast, and EMC, Marlo builds high-performing teams and talent strategies that support MariMed's rapid growth.





OUR RESULTS: Q3 2026 FINANCIAL PERFORMANCE

Q3 2026 FINANCIAL RESULTS

Revenue & Brand Momentum

- Revenue increased 8% year over year to $44.2 million, despite ongoing industry pricing pressure across several core markets
- Wholesale revenue grew 8% year over year, representing 44% of total revenue and driven by continued expansion of MariMed's leading edible and beverage brands
- Retail transactions increased 7% year over year, driven by continued growth in loyalty members and AOV

Profitability & Operating Discipline

- Generated positive operating cash flow during Q3 2026
- Maintained positive Adj. EBITDA for the 27th consecutive quarter, with Adj. EBITDA margin of 10.5%

Strategic Expansion

- Expanded licensing initiatives continue to support long-term growth opportunities and extend brand reach with limited capital investment

Revenue	$44.2 million
GAAP Gross Margin	38.8%
Non-GAAP Gross Margin*	40.0%
GAAP Net Loss	$3.5 million
Non-GAAP Net Loss*	$2.3 million
Adjusted EBITDA*	$4.7 million
Adjusted EBITDA Margin*	10.5%

* See Q3 2026 Non-GAAP Supplemental Information

BALANCE SHEET - END OF Q3 2026

Capital Structure

- Total assets of $198.3 million versus total liabilities of $151.3 million as of quarter-end
- Total debt of $78.2 million represented approximately 39% of total assets
- Balance sheet capacity continues to support investment in wholesale and retail growth initiatives

Operating Liquidity

- Generated $6.7 million of positive operating cash flow year-to-date through Q3 2026
- Operating working capital remained strong at $34.7 million

Strategic Financial Positioning

- Balance sheet structure supports continued investment in branded product expansion and market penetration initiatives
- Cash and cash equivalents of $10.4 million provide additional flexibility to fund growth initiatives

Cash and Cash Equivalents	$10.4 million
Total Assets	$198.3 million
Total Debt	$78.2 million
Total Liabilities	$151.3 million
Operating Working Capital*	$34.7 million

* See Q3 2026 Non-GAAP Supplemental Information

Q3 2026 YTD CASH FLOW

Cash Flow Category		Q3 2026 YTD Activity
Operating Activities	$6.654 million	Positive cash flow from operations
Investing Activities	-$1.555 million	Capital expenditures and license renewals/purchases
Financing Activities	-$3.622 million	~$3.5 million in scheduled debt and financed lease repayments
	$1.477 million	

Year-end Non-GAAP Supplemental information

Income (loss) from Operations to Adjusted EBITDA Reconciliation

(in '000s USD)	2020	2021	2022	2023	2024	2025
Income (loss) from operations	**14,440**	**26,535**	**19,879**	**14,269**	**2,609**	**(2,820)**
Depreciation of property and equipment	1,792	2,098	3,432	5,549	7,910	8,109
Amortization of acquired intangible assets	390	690	1,282	3,025	2,948	3,401
Inventory revaluation	-	-	-	-	3,667	5,559
Stock-based compensation	992	13,440	6,338	1,020	1,050	1,860
Severance	-	-	-	-	211	266
Acquisition-related and other	-	(266)	961	695	951	486
Adjusted EBITDA (non-GAAP measure)	**17,614**	**42,497**	**31,892**	**24,558**	**19,346**	**16,861**

Q3 2026 Non-GAAP Supplemental information

(in ‘000s USD, except where noted)

GAAP Income from operations	1,221
Depreciation of property and equipment	2,201
Amortization of acquired intangible assets	717
Stock-based compensation	335
Acquisition-related and other	183
Adjusted EBITDA	4,657

GAAP income from operations	2.8%
Depreciation of property and equipment	4.9%
Amortization of acquired intangible assets	1.6%
Stock-based compensation	0.8%
Acquisition-related and other	0.4%
Adjusted EBITDA margin	10.5%

Q3 2026 Non-GAAP Supplemental information

(in '000s USD, except where noted)

GAAP Gross margin	38.8%
Amortization of acquired intangible assets	1.2%
Non-GAAP Gross margin	40.0%

GAAP Net loss	(3,487)
Stock-based compensation	335
Amortization of acquired intangible assets	717
Severance	--
Acquisition-related and other	183
Non-GAAP Net loss	(2,252)

GAAP Working Capital	(6,593)
Mortgages and notes payable, current portion	3,214
Income taxes payable	34,221
Operating lease liabilities, current portion	2,120
Finance lease obligations, current portion	1,788
Non-GAAP Operating Working Capital	34,750



THANK YOU

For more information:
Email: ir@marimedinc.com

MariMed